Mann, Philipp

Phase 1 Assessment of the Safety and Immunogenicity of an mRNA- Lipid Nanoparticle Vaccine Candidate Against SARS-CoV-2 in Human Volunteers

Kremsner, P., Mann, P., Bosch, J., Fendel, R., Gabor, J. J., Kreidenweiss, A., Kroidl, A., Leroux-Roels, I., Leroux-Roels, G., Schindler, C., et al. (2020) · Wiener klinische Wochenschrift

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 199

Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial

Kremsner, P. G., Ahuad Guerrero, R. A., Arana-Arri, E., Aroca Martinez, G. J., Bonten, M., Chandler, R., Corral, G., De Block, E. J. L., Ecker, L., Gabor, J. J., et al. (2022) · The Lancet Infectious Diseases

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 172

Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study

Essink, B. J., Shapiro, C., Isidro, M. G. D., Bradley, P., Pragalos, A., Bloch, M., Santiaguel, J., Frias, M. V., Miyakis, S., Alves de Mesquita, M., et al. (2024) · Human Vaccines & Immunotherapeutics

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 8